In conclusion , NVBBs , but not VBBs , determine a lower reduction in cSBP than in pSBP .
However , the difference in treatment-induced SBP amplification changes between NVBB and VBB is nearly abolished after accounting for differences in heart rate changes
β-Blockers are less effective than other antihypertensive drug classes in reducing central systolic blood pressure ( cSBP ) as compared with peripheral SBP ( pSBP ) .
Whether this effect is less pronounced with vasodilating β-blockers ( VBB ) when compared with nonvasodilating β-blockers ( NVBB ) remains unsettled .
Differential Effects of Nebivolol and Metoprolol on Central Aortic Pressure and Left Ventricular Wall Thickness
The aim of this study was to investigate the effects of the vasodilating & bgr;-blocker nebivolol and the cardioselective & bgr;-blocker metoprolol succinate on aortic blood pressure and left ventricular wall thickness . We conducted a r and omized , double-blind study on 80 hypertensive patients . The patients received either 5 mg of nebivolol or 50 to 100 mg of metoprolol succinate daily for 1 year . Their heart rate , central and brachial blood pressures , mean arterial pressure , augmentation index , carotid-femoral pulse wave velocity , and left ventricular wall thickness were measured at baseline and at the end of the study . Nebivolol and metoprolol significantly reduced heart rate , brachial blood pressure , and mean arterial pressure to the same degree . However , reductions in central systolic and diastolic blood pressures , central pulse pressure , and left ventricular wall thickness were significant only in the nebivolol group . The change in left ventricular septal wall thickness was significantly correlated with central systolic blood pressure change ( r=0.41 ; P=0.001 ) and with central pulse pressure change ( r=0.32 ; P=0.01 ) . No significant changes in augmentation index or carotid-femoral pulse wave velocity were detected in either treatment group . This proof-of-principle study provides evidence to suggest that & bgr;-blockers with vasodilating properties may offer advantages over conventional & bgr;-blockers in antihypertensive therapy ; however , this remains to be tested in a larger trial
In conclusion , NVBBs , but not VBBs , determine a lower reduction in cSBP than in pSBP .
However , the difference in treatment-induced SBP amplification changes between NVBB and VBB is nearly abolished after accounting for differences in heart rate changes
β-Blockers are less effective than other antihypertensive drug classes in reducing central systolic blood pressure ( cSBP ) as compared with peripheral SBP ( pSBP ) .
Whether this effect is less pronounced with vasodilating β-blockers ( VBB ) when compared with nonvasodilating β-blockers ( NVBB ) remains unsettled .